Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis
© Chen et al; licensee BioMed Central Ltd. 2009
Received: 16 March 2009
Accepted: 28 April 2009
Published: 28 April 2009
Proteins associated with the late endosome (LE) appear to play a central role in the envelopment of a number of taxonomically diverse viruses. How viral proteins interact with LE-associated proteins to facilitate envelopment is not well understood. LE-derived transport vesicles form through the interaction of Rab9 GTPase with cargo proteins, and TIP47, a Rab9-specific effector protein. Vaccinia virus (VV) induces a wrapping complex derived from intracellular host membranes to envelope intracellular mature virus particles producing egress-competent forms of virus.
We show that VV p37 protein associates with TIP47-, Rab9-, and CI-MPR-containing membranes. Mutation of a di-aromatic motif in p37 blocks association with TIP47 and inhibits plaque formation. ST-246, a specific inhibitor of p37 function, inhibits these interactions and also blocks wrapped virus particle formation. Vaccinia virus expressing p37 variants with reduced ST-246 susceptibility associates with Rab9 and co-localizes with CI-MPR in the presence and absence of compound.
These results suggest that p37 localizes to the LE and interacts with proteins associated with LE-derived transport vesicle biogenesis to facilitate assembly of extracellular forms of virus.
Vaccinia virus (VV) is the prototypical member of Orthopoxviridae, which replicates within the cytoplasm of permissive cells. At least four distinct types of enveloped infectious virus particles are produced during productive infection: mature virus, also referred to as intracellular mature virus or IMV, wrapped virus, also called intracellular enveloped virus (IEV), and two forms of extracellular virus (EV), cell-associated enveloped virus (CEV), and extracellular enveloped virus (EEV) [1, 2]. IEV particles are precursors of extracellular forms of virus and are created by the wrapping of IMV particles in virus-modified membranes [3, 4]. Electron microscopic evidence suggests that these membranes are derived from the TGN or post-TGN vesicles [3, 5].
Envelopment of IMV particles requires the activity of p37, a highly conserved 37 kDa peripheral membrane protein encoded by the F13L gene . Vaccinia p37 localizes to the trans Golgi, plasma and endosomal membranes and is shuttled between these various compartments through a clathrin-mediated endosomal pathway . Golgi localization and intracellular trafficking of p37 requires palmitylation of two cysteine residues at positions 185 and 186  as well as a putative phospholipase motif composed of histidine, lysine, aspartic acid (HKD) . Targeted mutagenesis of these cysteine residues or amino acids within the HKD motif alters the intracellular distribution of p37 and inhibits IMV wrapping [9–12].
Vesicular transport and membrane trafficking are regulated by Rab proteins which are small (20–29 kDa) GTPases that belong to the Ras super family of proteins . GTP-bound Rab proteins serve in cargo selection and act as scaffolds to nucleate vesicle assembly through interactions with cargo and rab-specific effector proteins . A number of viruses that derive their envelopes from internal host membranes have been shown to interact with host components associated with the late endosome (LE) trafficking pathway [14–17]. The role of these virus-host interactions in the formation of the virus membrane is an area currently under investigation.
The LE is enriched for Rab9 protein that mediates recycling of cation-dependent mannose-6-phosphate receptor (CD-MPR) and cation-independent mannose-6-phosphate receptor (CI-MPR) from the LE to the trans Golgi network (TGN) . Rab9-dependent recycling of CI-MPR is mediated through interactions with the tail interacting protein of 47 kDa (TIP47), a Rab9-specific effector [19, 20]. TIP47 binds to a proline-rich motif found within the C-terminus of CI-MPR  and a diaromatic tyrosine-tryptophan (YW) motif found within the cytosolic tail of CD-MPR . Likewise, TIP47 has been shown to interact with the HIV Env protein through a similar diaromatic YW motif , as well as the MA domain of the HIV Gag protein by way of a 9-residue region situated at the N-terminus . RNAi-mediated depletion of Rab9 inhibited replication of human immunodeficiency virus type 1, filoviruses, and measles virus, which is consistent with Rab9-containing vesicles playing a role in virus assembly .
ST-246 is a small-molecule (MW = 376), potent pharmacological inhibitor of orthopoxvirus dissemination. Genetic resistance to ST-246 maps to the V061 gene product of cowpox virus, which is the homolog of VV p37 . The small plaque phenotype observed in the presence of compound and the ability of the compound to prevent dissemination in vivo is consistent with the inhibition of extracellular virus formation. Thus, ST-246 is a useful tool for studying the mechanism of p37-dependent extracellular virus formation.
In this manuscript, plaque formation and wrapped virus formation were found to be dependent upon interaction of p37 with host LE-associated proteins in membrane fractions of infected cells. The association of p37 with Rab9 and CI-MPR but not, p230, a TGN-associated protein, could be inhibited by ST-246. Furthermore, mutation of a diaromatic amino acid motif in p37 reduced the interaction between p37 and TIP47 in membrane fractions from infected cell lysates, thereby preventing the formation wrapped virus particles. Taken together, these results suggest that p37 interacts with host proteins involved in LE trafficking to facilitate envelopment of IMV particles.
RK-13, BSC-40, BGMK, and Vero cells were obtained from American Type Culture Collection and maintained at 37°C and 5% CO2 in MEM medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 2 mM glutamine (Invitrogen) and 10 μg/ml gentamicin (Invitrogen).
Immunofluorecent staining was performed using antibodies against GM130, p230 (BD Biosciences Pharmingen), and CI-MPR (Affinity BioReagents) at a concentration of 20 μg/ml. The secondary antibody was anti mouse-Alexa 594 (Molecular Probes) and was used at a concentration of 1 μg/ml. Antisera against viral proteins, B5 and L4, were generated at SIGA Technologies, Inc The primary antibodies used for immunoprecipitation and immunoblotting were: anti-CI-MPR (Affinity BioReagents), p230, polyclonal anti-GFP (Invitrogen), monoclonal anti-GFP (BD BioSciences) and polyclonal TIP47 (C-20) (Santa Cruz BioTechnology, Inc). Secondary antibodies included anti goat-HRP (Santa Cruz Biotechnologies), anti-mouse-HRP and anti-rabbit-HRP (Bio-Rad).
Buoyant density centrifugation of radiolabeled virions
RK-13 cells were seeded in two 150 cm2 diameter dishes at 1 × 107 cells per dish. The cultures were infected with 10 PFU/cell of vaccinia virus strain IHD-J in the absence or presence of 10 μM ST-246. At 3 hours post infection (hpi) the culture media was aspirated and replaced with thymidine-deficient MEM containing 12 μCi/ml of [methyl-3H]-thymidine (Amersham Biosciences GE Healthcare), either in the presence or absence of 10 μM ST-246. At 24 hpi, the culture supernatants were centrifuged at 4000 × g at 25°C for 5 min to remove cell debris. The supernatants were layered onto a 7-ml cushion of 36% sucrose in PBS and centrifuged at 40,000 × g at 4°C for 80 min. The pellet (extracellular virus) was resuspended in 1 ml PBS and stored on ice. BSC-40 cell monolayers were washed in 5 ml of PBS and harvested by scraping into 1 ml of hypotonic buffer (50 mM Tris pH 8.0, 10 mM KCl) and allowed to swell on ice for 10 min. The cells were subjected to two freeze-thaw cycles and then homogenized by 20 strokes in a Dounce homogenizer using a type-A pestle to release virus. The cellular debris was removed by centrifugation at 700 × g for 10 min at 4°C. The supernatants were layered on a 7-ml cushion of 36% sucrose in PBS and centrifuged at 40,000 × g for 80 min at 4°C. The pellet (cell-associated virus) was resuspended in 1 ml PBS and stored on ice. Both extracellular and cell-associated samples were layered on top of preformed CsCl gradients. The gradients were prepared in ultracentrifuge tubes by overlaying from bottom to top 3 ml of 1.30 g/ml, 4 ml of 1.25 g/ml and 5 ml of 1.20 g/ml CsCl solution, respectively. The samples were centrifuged at 100,000 × g for 3 hr at 15°C. Fractions (500 μL) were collected from the bottom of each gradient. Radiolabeled material from 20 μl of each fraction was quantified by liquid scintillation counting.
Generation of recombinant VV
Marker rescue approach was used to generate vvF13L-GFP as previously described . Briefly, a gel-purified PCR product of F13L-GFP containing 1 kb of flanking DNA was co-transfected with genomic DNA of VV strain WR using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations into BGMK cells infected with 2 PFU/cell of Shope fibroma virus 1 h prior to transfection. At 3 days post-transfection, progeny virus was plated onto BSC-40 cells and GFP-positive foci were isolated and subjected to three rounds of plaque purification. In addition, an F13L-deletion virus (vvΔF13LGFP) was created and purified as described above. In this recombinant mutant virus, the GFP open reading frame replaced the native F13L sequence following nucleotide 18.
Plasmid construction and site-directed mutagenesis
A gel-purified PCR product of F13L-GFP containing 1 kb of flanking DNA (forward primer 5'-CATCCATCCAAATAACCCTAG-3'; reverse primer 5'-AGATACTCCTAGATACATACCATC-3') was TOPO cloned into pCR2.1 (Invitrogen) according to the manufacturer's instructions. Selected residues underwent targeted mutagenesis using the QuikChange® Multi Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. Mutagenesis primers were designed using the QuikChange® Primer Design Program (Stratagene). Plasmid DNA was extracted using a QIAprep Spin Miniprep Kit (Qiagen). Residue changes were verified by DNA sequencing.
Trans complementation assay
PCR products for transfection were prepared from each mutant plasmid using forward primer 5'-CTCTAATCGTGGAGATGATGATAGTTTAAGC-3' and reverse primer 5'-AGATACTCCTAGATACATACCATC-3'. PCR constructs were purified using the QIAquick PCR Purification Kit (Qiagen) and quantified by fluorometery. BSC-40 cells were seeded into 6-well tissue culture plates at a density of 3 × 105 cells/ml one day prior to transfection and then infected with 100 pfu/well of vvΔF13LGFP. At 1 hpi, the viral inoculum was removed and replaced with 1.5 ml of infection media. Transfections were carried out using 4 μg of purified PCR product and 10 μl of Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. Following an overnight incubation, the transfection inoculum was removed and replaced with 2.5 ml of infection media containing 1.5% methylcellulose. On day 3 post-infection, the plates were fixed with 5% glutaraldehyde in PBS and stained with 0.5% crystal violet containing 5% methanol.
BSC-40 cells were infected with 5 PFU/cell of the wild type recombinant virus, vvF13LGFP. At 12 hpi, cells were washed once with PBS and harvested in 3 ml of HES buffer containing a protease inhibitor cocktail (1 mM EDTA, 250 mM sucrose, 20 mM HEPES, pH 7.4). The suspension was pelleted by centrifugation at 700 × g at 4°C for 5 min and the remaining volume was adjusted to 1.5 ml in HES buffer and passed 8 times through a 23 g needle followed by Dounce homogenization. After centrifugation at 800 × g for 5 min, the cleared cell lysate was centrifuged at 4,000 × g for 10 min to generate a low speed pellet and a low speed supernatant. The supernatant was cleared of mature virion particles by loading 1.7 ml onto a 36% sucrose cushion (Tris-HCl, pH 9.0) and subjected to centrifugation at 34,380 × g for 55 min at 4°C using a Beckman SW 60Ti rotor. The supernatant was collected and further centrifuged at 350,000 × g for 30 min to generate a high speed pellet enriched for LE and microsomes. The pelleted material was resuspended in 90 μl of HES buffer containing a protease inhibitor cocktail and divided in half. 45 μl was dedicated as the isolated membrane fraction and used as input controls. The remaining 45 μl was employed in immunoprecipitation procedures.
Immunoprecipitation and immunoblotting
The protein content of each sample obtained from the membrane fractionation was quantified by a protein assay kit (Bio-Rad), adjusted to a concentration of 1 mg/ml and then preadsorbed with 25 μl of protein A-Sepharose 4B (50% slurry, Amersham Biosciences) at 4°C for 1 h to reduce non-specific protein-bead interactions. The samples were centrifuged at 500 × g for 15 s to remove the protein A-Sepharose 4B beads. Primary antibody was added to the supernatants to a final concentration of 2 μg/ml and incubated at 4°C for 12 h. Antibody-bound complexes were incubated with 40 μl of protein A-Sepharose (50% slurry) for 4°C for 2 h. Immunoprecipitates were collected by centrifugation at 500 × g for 15 sec and washed four times with buffer. Immunoprecipitates were resolved by 4–12% SDS-PAGE. Proteins were transferred to nitrocellulose membranes (Hybond-C, Amersham) and probed with specific antibodies to selected viral and cellular targets. Immune complexes were detected using ECL Western blotting detection kit (Amersham) according to the manufacturer's instructions and exposed to MR-type X-ray film (Kodak). Images for selected figures were collected and processed using Adobe Photoshop software followed by densitometry analysis using a BioRad Universal HoodII and Quantity I software package.
Immunofluorescence analysis and confocal microscopy
Chamber slides (Fisher Scientific) containing BSC-40 cells were infected at 8 PFU per cell or transfected with 1 μg of plasmid DNA per well using Lipofectamine 2000 (Invitrogen) in the presence and absence of 10 μM ST-246. At 12–16 hpi, cells were washed in phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde for 15 min at 25°C, rinsed with PBS, and permeabilized with 0.2% TritonX-100 for 5 min. Slides were blocked with 10% goat serum (Sigma Aldrich) in PBS for 30 min and then incubated for 1 h at 25°C with primary antibodies in goat serum-PBS. Cells were washed with PBS, incubated for 30 min at 25°C with secondary antibodies in goat-serum-PBS followed by three washes in PBS. The samples were mounted in ProLong Gold Antifade Reagent (Invitrogen Molecular Probes) containing DAPI to stain nuclear DNA. Analysis was performed using a Zeiss LSM 510 confocal laser-scanning microscope. Images were processed using LSM 510 Acquisition and Adobe Photoshop software.
ST-246 was synthesized at Pharmacore, (High Point, NC) and was dissolved in dimethyl sulfoxide (DMSO) (Sigma Aldrich) to a concentration of 10 mM. Where indicated, ST-246 was used at a concentration of 10 μM.
Results and discussion
ST-246 prevents the formation of wrapped viral particles
Immunoblot analysis of fractions from the equilibrium centrifugation experiment was conducted to confirm the identity of each type of viral particle in peak fractions. Immunoblots were probed with anti-L4 antiserum to detect viral cores and anti-B5 antiserum which is a component specific to wrapped viral particles (Fig. 1B). In the absence of ST-246, the L4 protein was detected in all fractions with a density between 1.168 g/ml and 1.300 g/ml, which is consistent with this protein being a component of all forms of VV particles. B5 protein was detected in fractions with a density between 1.168 g/ml and 1.250 g/ml, suggesting that these fractions contained IEV and CEV particles. In the presence of ST-246, L4 protein was detected in fractions with a density between 1.250 g/ml and 1.300 g/ml, while B5 protein was not detected in any of the fractions. Taken together, these results demonstrate that ST-246 inhibits wrapped virus formation and prevents extracellular virus production.
p37 co-precipitates with TIP47 in infected cells
To demonstrate antibody specificity, total cell lysates were prepared from BSC40 cells that were either mock-infected or infected with vvWR, vvGFP, vvΔF13LGFP, or vvF13LGFP. A portion of the lysate was immunoprecipitated with a polyclonal antibody to GFP. Immunoblots of the lysate material pre- and post-immunoprecipitation were probed with a monoclonal antibody to GFP (Fig. 2B). A band of approximately 66 kDa was observed on the immunoblots in samples (Fig. 2B, lane 3 and 8) infected with vvF13L-GFP migrating at the predicted size of the p37-GFP fusion protein. A band of approximately 27 kDa was observed in samples (Fig. 2B lane 4,5,9, and 10) infected with vvGFP and vvΔF13LGFP corresponding to the size of GFP. No bands were observed in mock-infected samples (Fig. 2B lanes 1 and 6) or samples infected with vvWR (Fig. 2B, lanes 2 and 7). These results suggest that the both monoclonal and polyclonal antibodies specific for GFP do not cross react with other viral and cellular proteins.
A conserved YW motif within p37 is required for complimentation of an F13L-deletion virus
VV recombinants containing deletions in F13L produced normal levels of IMV particles but failed to form plaques within a 3-day incubation period at 37°C. After a 7-day incubation period plaques generated by F13L-deleted recombinants were comparable in size to plaques generated by wild-type virus after a 1-day incubation period. This strong plaquing phenotype was used to measure the ability of mutated F13L alleles to complement plaque formation of an F13L-deleted virus. Consistent with the co-immunoprecipitation data presented in Fig. 3C, p37 variants containing alanine substitutions at either Y253 or W254 respectively, were unable to complement plaque formation of an F13L-deleted virus (Fig. 3B). Alanine substitutions at positions surrounding the YW motif did not block complementation of the F13L-deleted virus (Fig. 3B) suggesting that the YW motif and not amino acids surrounding this motif are required for extra cellular virus formation. Complementing plaque formation by transfecting PCR products encoding p37 could occur through recombination of the F13L alleles into the viral genome or by transient expression of active p37. This distinction, however, does not affect the interpretation of the experiment. Taken together, these observations suggest that the aromatic nature of the YW motif is required for plaque formation and that the YW motif contributes to the interaction of p37 with TIP47 in membrane fractions of infected cells.
Confocal laser scanning microscopy was conducted to rule out the possibility that the p37 expressed from the Y253A and W254A mutants was mislocalized and no longer capable of complementing plaque formation of the F13L-deleted virus. BSC-40 cells were infected with VV, strain WR, at an MOI of 1 and then transfected with 200 ng of PCR-generated DNA encoding wild-type or mutant p37-GFP alleles. Approximately 50 to 100 infected and transfected cells per mutant construct were evaluated for altered intracellular localization of p37-GFP. The fluorescence profile obtained from the p37-GFP fusion protein was evaluated against a TGN marker and found to be indistinguishable from wild type p37 suggesting that alanine substitution in and around the YW motif does not alter the sub-cellular localization of p37 (Fig. S1).
ST-246 inhibits association of p37-GFP with LE proteins in membrane fractions from infected cells
ST-246 inhibits the co-localization of p37-GFP with LE proteins in the context of viral infection
Since the effect of ST-246 on co-localization of p37-GFP with LE proteins was observed in the context of virus infection, it was important to determine whether this effect required other viral proteins or was specific for p37. Vero cells were transfected with the plasmid pSI-F13L-GFP expressing p37-GFP in the presence or absence of ST-246 and analyzed by immunofluorescence and confocal microscopy (Fig. 5B). The pattern of p37-GFP signal was not affected by the presence of ST-246 and p37-GFP appeared to co-localize with p230 and CI-MPR in the presence and absence of ST-246 as measured by the intensity of the yellow color of the merged images. These results suggest that ST-246 inhibits a virus-specific activity required for co-localization of p37 with LE proteins and is consistent with the observation that functional p37 is required for co-localization of the EEV-specific envelope protein, B5, to post-Golgi vesicles .
ST-246 reduces p37-GFP association with vaccinia virus B5 protein and LE proteins in membrane fractions from infected cells
p37 expressed from an ST-246-resistant VV variant interacts with Rab9 and B5 in the presence and absence of compound
To support the co-immunoprecipitation studies described above, the intracellular localization of p37, p230, and CI-MPR within cells infected by the ST-246R variant in the presence and absence of ST-246 was examined by confocal microscopy (Fig. 7C). The images presented are representative of 50–100 infected cells throughout the entire sample and were confirmed by thin-slice (Z-stack) analysis. As observed in previous experiments (Fig. 4 and data not shown), p37 co-localized with p230 in the presence and absence of ST-246 (indicated by the pattern of yellow in the merged images) (Fig. 7C, left). Moreover, unlike p37 expressed from wild type vaccinia virus infected cells, the p37 expressed from the ST-246R variant co-localized with CI-MPR in the presence and absence of ST-246 (Fig. 7C, right). Taken together, these results suggest that ST-246 inhibits the formation of a membrane complex containing p37 and LE proteins.
A prerequisite for production of extracellular forms of VV is the assembly of IEV particles that involves wrapping of IMV particles in virus modified membranes derived from the host. Induction of this so-called wrapping complex, also described as an envelope precursor membrane or a post-TGN-vesicle, requires activities associated with the p37 protein . The wrapping complex incorporates viral and cellular proteins that would normally co-localize to the Golgi and LE and is also enriched for selected viral outer envelope proteins [1, 5]. The wrapping complex is thought to be the biologically active entity that enwraps IMV particles to produce IEV particles [5, 11]. In this manuscript, we show that induction of a membrane complex containing viral p37 and B5 proteins and host LE proteins involved in transport vesicle biogenesis requires interaction of p37 with LE proteins and can be inhibited by ST-246, a specific orthopoxvirus egress inhibitor.
The LE has been implicated as a potential source of membranes for the formation of wrapped virus [4, 11]. These observations led us to focus on the involvement of proteins associated with the LE in extracellular virus production. Rab9 and TIP47 are both enriched in the LE and form a scaffold for transport vesicle formation that shuttles CI-MPR from the LE to the Golgi. Immunoprecipitation of p37-containing membrane fractions co-precipitated TIP47 and Rab9. Targeted alanine (A) substitutions of a conserved diaromatic (YW) motif in p37, the same motif that has been shown to mediate the interaction of TIP47 with HIV Env , blocked the association of p37 with TIP47 in membrane fractions from infected cells. Furthermore, A substitutions within the YW motif that reduced interactions with TIP47 also failed to complement plaque formation of an F13L-deleted virus. Maintaining the diaromatic nature of the YW motif retained the ability of TIP47 to associate with p37 and rescue the small plaque phenotype of the F13L-deleted virus suggesting that the diaromatic nature of this motif is necessary for extracellular virus formation. In addition, ST-246 specifically blocked association of p37 with Rab9, TIP47, and CI-MPR-containing membranes as well as with the VV B5 protein but not p230, a TGN marker protein, in the context of viral infection. These data support a model whereby p37-containing membranes associate with host proteins required for induction of LE transport vesicles to facilitate EV particle production.
The observation that the interaction between Rab9 and CI-MPR appeared to be ST-246-sensitive only in the context of viral infection suggests that Rab9-mediated transport pathways are occupied by p37-dependent virus-specific processes. Viral p37 is expressed at high levels and represents a major source of cargo within the infected cell, potentially sequestering available Rab9-containing membranes to form the wrapping complex. By disrupting p37-Rab9 interactions, ST-246 blocks the formation of a membrane complex involved in EV biogenesis and perhaps prevents Rab9-dependent vesicle formation and association of cellular cargo, such as CI-MPR, with Rab9-containing membranes. While this phenomenon remains under investigation, it exemplifies the high degree of specificity of ST-246 for infected cells and may explain the observation that ST-246 has little or no toxicity in cell culture and in animals.
The origin of the virus modified membranes that form the wrapping complex has been controversial. Both the TGN and endosomes have been implicated as the site of IMV wrapping [3, 4, 11, 28]. Immuno-EM studies have shown that the virus-modified membrane system, which appears as a double membrane structure 'modified' with viral membrane proteins, could be stained with lectins specific for glycoproteins that have been processed in the TGN but not the cis or medial Golgi . Moreover, Rab5 and Rab7, proteins normally associated with early and late endosomes, respectively, were not found associated with wrapping membranes . These studies also show that endocytic tracers (HRP and BSA-gold) were found in the lumen of the wrapping cisternae. In addition, a number of IMV particles could be found associated with endosomes. Our data is consistent with these observations and suggests that the virus modified membranes involved in EV formation are derived from the late endosome and are induced by interaction of p37 with LE proteins involved in transport vesicle biogenesis.
Rab proteins are required for transport vesicle biogenesis and are essential components of the membrane trafficking system in the cell. Rab9 is predominantly localized to the LE compartment and plays a role in cargo selection and transport vesicle formation through interactions with TIP47 [19, 20]. RNAi-mediated disruption of this pathway reduces replication of human immunodeficiency virus, filoviruses, and measles virus suggesting a common theme among diverse virus families that acquire their envelope from this subcellular compartment . Although RNAi-mediated knock-down of Rab9 or expression of dominant-negative mouse-specific Rab9 allele did not inhibit plaque formation of VV, strain IHDJ (data not shown), the association of p37 with LE components correlates with induction of a p37-containing membrane complex containing LE proteins and efficient plaque formation. The inability to block plaque formation by interfering with Rab9 expression or activity could be due to residual Rab9 activity remaining after RNAi knock-down or species incompatibility between dominant-negative mouse Rab9 alleles and primate-specific host components involved in membrane vesicle formation. Alternatively, vaccinia virus may be less discriminating in the use of Rab proteins and other host components involved in wrapping complex formation. Indeed, vaccinia virus can use multiple host kinases to facilitate release of cell-associated extracellular virus into the extracellular space providing precedent for this idea .
The p37 protein may participate directly in the biogenesis of the wrapping complex through a conserved histidine-lysine-aspartate (HKD) phospholipase motif that has been shown to be essential for IMV wrapping. Targeted mutagenesis of this motif or addition of a specific phospholipase D inhibitor, reduced IMV wrapping and inhibited extracellular particle formation [5, 11]. This result suggests that phospholipase activity is important for p37 function. Indeed, purified p37 has been shown to have broad-spectrum lipase activity . The role of lipase activity in p37 function is unclear but may involve p37-induced membrane alterations, since transfection studies have shown that deletion of the HKD motif inhibited the formation of p37-induced vesicles . Whether or not ST-246 inhibits the putative phospholipase activity is currently under investigation. Taken together, our results suggest that p37-induced vesicle formation requires association of p37 with host proteins associated with LE transport vesicle biogenesis. Thus, p37 may interact with LE proteins, mimicking cellular cargo, to nucleate a membrane complex essential for the envelopment of IMV particles.
This work was supported by National Institute of Allergy and Infectious Disease grant 5R44AI056409-04 to R.J. We would like to thank Doug Grosenbach, Kevin Jones, Sean Amberg, Robert Allen, Rebecca Wilson and Tove' Bolken for critical review of the manuscript.
- Smith GL, Vanderplasschen A, Law M: The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002, 83: 2915-2931.View ArticlePubMedGoogle Scholar
- Moss B: Poxviridae and their replication. In Fields Virology. Edited by: Knipe B, Howley P. New York: Raven Press; 2001:2849-2884.Google Scholar
- Schmelz M, Sodeik B, Ericsson M, Wolffe EJ, Shida H, Hiller G, Griffiths G: Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol 1994, 68: 130-147.PubMed CentralPubMedGoogle Scholar
- Tooze J, Hollinshead M, Reis B, Radsak K, Kern H: Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. Eur J Cell Biol 1993, 60: 163-178.PubMedGoogle Scholar
- Husain M, Moss B: Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D. J Virol 2002, 76: 7777-7789. 10.1128/JVI.76.15.7777-7789.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Blasco R, Moss B: Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol 1991, 65: 5910-5920.PubMed CentralPubMedGoogle Scholar
- Husain M, Moss B: Role of receptor-mediated endocytosis in the formation of vaccinia virus extracellular enveloped particles. J Virol 2005, 79: 4080-4089. 10.1128/JVI.79.7.4080-4089.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Grosenbach DW, Ulaeto DO, Hruby DE: Palmitylation of the vaccinia virus 37-kDa major envelope antigen. Identification of a conserved acceptor motif and biological relevance. J Biol Chem 1997, 272: 1956-1964. 10.1074/jbc.272.3.1956View ArticlePubMedGoogle Scholar
- Roper RL, Moss B: Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein. J Virol 1999, 73: 1108-1117.PubMed CentralPubMedGoogle Scholar
- Grosenbach DW, Hruby DE: Analysis of a vaccinia virus mutant expressing a nonpalmitylated form of p37, a mediator of virion envelopment. J Virol 1998, 72: 5108-5120.PubMed CentralPubMedGoogle Scholar
- Husain M, Moss B: Vaccinia virus F13L protein with a conserved phospholipase catalytic motif induces colocalization of the B5R envelope glycoprotein in post-Golgi vesicles. J Virol 2001, 75: 7528-7542. 10.1128/JVI.75.16.7528-7542.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Sung TC, Roper RL, Zhang Y, Rudge SA, Temel R, Hammond SM, Morris AJ, Moss B, Engebrecht J, Frohman MA: Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity. Embo J 1997, 16: 4519-4530. 10.1093/emboj/16.15.4519PubMed CentralView ArticlePubMedGoogle Scholar
- Grosshans BL, Ortiz D, Novick P: Rabs and their effectors: achieving specificity in membrane traffic. Proc Natl Acad Sci USA 2006, 103: 11821-11827. 10.1073/pnas.0601617103PubMed CentralView ArticlePubMedGoogle Scholar
- Honeychurch KM, Yang G, Jordan R, Hruby DE: The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus. J Virol 2007, 81: 7310-7315. 10.1128/JVI.00034-07PubMed CentralView ArticlePubMedGoogle Scholar
- Crump CM, Yates C, Minson T: Herpes simplex virus type 1 cytoplasmic envelopment requires functional Vps4. J Virol 2007, 81: 7380-7387. 10.1128/JVI.00222-07PubMed CentralView ArticlePubMedGoogle Scholar
- Murray JL, Mavrakis M, McDonald NJ, Yilla M, Sheng J, Bellini WJ, Zhao L, Le Doux JM, Shaw MW, Luo CC, et al.: Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J Virol 2005, 79: 11742-11751. 10.1128/JVI.79.18.11742-11751.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW Jr, Sowder RC 2nd, Barsov E, Hood BL, Fisher RJ, et al.: Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 2006, 80: 9039-9052. 10.1128/JVI.01013-06PubMed CentralView ArticlePubMedGoogle Scholar
- Orsel JG, Sincock PM, Krise JP, Pfeffer SR: Recognition of the 300-kDa mannose 6-phosphate receptor cytoplasmic domain by 47-kDa tail-interacting protein. Proc Natl Acad Sci USA 2000, 97: 9047-9051. 10.1073/pnas.160251397PubMed CentralView ArticlePubMedGoogle Scholar
- Carroll KS, Hanna J, Simon I, Krise J, Barbero P, Pfeffer SR: Role of Rab9 GTPase in facilitating receptor recruitment by TIP47. Science 2001, 292: 1373-1376. 10.1126/science.1056791View ArticlePubMedGoogle Scholar
- Diaz E, Pfeffer SR: TIP47: a cargo selection device for mannose 6-phosphate receptor trafficking. Cell 1998, 93: 433-443. 10.1016/S0092-8674(00)81171-XView ArticlePubMedGoogle Scholar
- Nair P, Schaub BE, Rohrer J: Characterization of the endosomal sorting signal of the cation-dependent mannose 6-phosphate receptor. J Biol Chem 2003, 278: 24753-24758. 10.1074/jbc.M300174200View ArticlePubMedGoogle Scholar
- Blot G, Janvier K, Le Panse S, Benarous R, Berlioz-Torrent C: Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for env incorporation into virions and infectivity. J Virol 2003, 77: 6931-6945. 10.1128/JVI.77.12.6931-6945.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Lopez-Verges S, Camus G, Blot G, Beauvoir R, Benarous R, Berlioz-Torrent C: Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. Proc Natl Acad Sci USA 2006, 103: 14947-14952. 10.1073/pnas.0602941103PubMed CentralView ArticlePubMedGoogle Scholar
- Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, et al.: An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 2005, 79: 13139-13149. 10.1128/JVI.79.20.13139-13149.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Marra P, Maffucci T, Daniele T, Tullio GD, Ikehara Y, Chan EK, Luini A, Beznoussenko G, Mironov A, De Matteis MA: The GM130 and GRASP65 Golgi proteins cycle through and define a subdomain of the intermediate compartment. Nat Cell Biol 2001, 3: 1101-1113. 10.1038/ncb1201-1101View ArticlePubMedGoogle Scholar
- Gleeson PA, Anderson TJ, Stow JL, Griffiths G, Toh BH, Matheson F: p230 is associated with vesicles budding from the trans-Golgi network. J Cell Sci 1996,109(Pt 12):2811-2821.PubMedGoogle Scholar
- Mesa R, Salomon C, Roggero M, Stahl PD, Mayorga LS: Rab22a affects the morphology and function of the endocytic pathway. J Cell Sci 2001, 114: 4041-4049.PubMedGoogle Scholar
- Hiller G, Weber K: Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment. J Virol 1985, 55: 651-659.PubMed CentralPubMedGoogle Scholar
- Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, et al.: Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005, 11: 731-739. 10.1038/nm1265View ArticlePubMedGoogle Scholar
- Baek SH, Kwak JY, Lee SH, Lee T, Ryu SH, Uhlinger DJ, Lambeth JD: Lipase activities of p37, the major envelope protein of vaccinia virus. J Biol Chem 1997, 272: 32042-32049. 10.1074/jbc.272.51.32042View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.